Note: Descriptions are shown in the official language in which they were submitted.
CA 2793672 2017-03-24
WO 2011/116393 PCT/US2011/029261
DRAINAGE SYSTEMS FOR EXCESS BODY FLUIDS
TECHNICAL FIELD
[0002] The present technology relates generally to draining excess body
fluids. In
particular, several embodiments are directed toward body fluid drainage
systems with
enhanced drainage regulation and associated methods.
BACKGROUND
[0003] A variety of medical conditions cause the collection of excess body
fluids within
the human body. Hydrocephalus, for example, is an accumulation of excess
cerebrospinal
fluid ("CSF") in the ventricles of the brain that increases intracranial
pressure ("ICP"). This
condition can be caused by the inability to reabsorb CSF, impaired CSF flow,
or excessive
production of CSF. Acute accumulations of excess CSF can also occur from brain
trauma,
brain hemorrhaging, strokes, brain tumors, spinal fluid leaks, meningitis, and
brain abscesses.
When left untreated, hydrocephalus and other excess accumulations of CSF can
progressively
enlarge the ventricles of the brain, which can increase ICP and cause
convulsions, mental
disabilities, and eventually death.
[0004] Treatment for hydrocephalus generally requires the installation of a
CSF shunt
that drains CSF from the brain to an alternate location that can collect the
excess CSF or
reabsorb it into the body. A ventriculoperitoneal shunt ("VPS"), for example,
includes a
subcutaneously installed catheter inserted in the lateral ventricle (i.e., a
site of excess CSF)
and in fluid communication with the peritoneal cavity to facilitate
reabsorbtion of the excess
CSF into the body. A mechanical valve, generally implanted flush with the
skull, can
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
regulate CSF flow through the catheter. Recent innovations have resulted in
VPSs that can
regulate CSF movement based on static pressure parameters. For example, an
external
magnetic field can be applied to the implanted VPS to change the set point
pressure of the
valve.
[0005] Similar to hydrocephalus, acute accumulations of CSF are treated by
shunting
excess CSF to an alternate location. For example, temporary CSF diversion
generally
includes the installation of an external ventricular drain ("EVD") that
funnels CSF from the
lateral ventricle to an external drainage chamber, and thereby reduces the
intracranial CSF
volume and lowers ICP. Alternatively, temporary CSF diversion can include
placing a
lumbar drain ("LD") at the base of the spine, and draining CSF from the lumbar
region to an
external drainage chamber. Despite having different insertion points, EVDs and
LDs use the
similar components to control drainage.
[0006] In general, temporary and more permanent CSF diversion devices
(e.g., VPSs)
include similar features, and thus incur many of the same complications.
Infection, for
example, can be a significant risk factor both during and after implantation
of a CSF shunt.
When an infection occurs, the entire CSF shunt must be removed, and the
patient must
generally undergo 10-14 days of IV antibiotics and re-internalization of a new
CSF shunt.
Mechanical failure can occur within each component of a CSF shunt, and
generally requires
the replacement of the failed component(s). The inlet of the catheter, for
example, can incur
in-growth of intraventricular tissue. Valves can fail due to debris build-up
(e.g., blood,
protein) within the valve, and the outlet of the catheter can fail by
fracturing, becoming
obstructed, or tethering within scar tissue. These mechanical failures,
infections, and other
complications cause a majority of implanted CSF shunts to fail within two
years and nearly
all shunts fail within ten years. Due to this unreliability and the necessity
to locally monitor
and adjust ICPs, conventional CSF shunts require frequent intervention by
medical
professionals.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1A is a schematic view of an internal body fluid drainage
system
installed within a patient in accordance with an embodiment of the present
technology.
[0008] Figure 1B is a schematic view of an external body fluid drainage
system
installed in a patient in accordance with an embodiment of the present
technology.
2
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
[0009] Figure 2A is an enlarged schematic, cross-sectional view of a valve
device in
accordance with an embodiment of the present technology.
[0010] Figure 2B is an enlarged schematic, cross-sectional view of a valve
device in
accordance with another embodiment of the present technology.
[0011] Figures 3A-3J are side views of actuators for a valve device in
accordance with
embodiments of the present technology.
[0012] Figures 4A and 4B are side and perspective views, respectively, of
reservoirs for
a body fluid drainage system in accordance with embodiments of the present
technology.
[0013] Figure 5A is a schematic, cross-sectional top plan view of
unobstructed
antegrade flow through a valve device of a body fluid drainage system in
accordance with an
embodiment of the present technology.
[0014] Figure 5B is a schematic, cross-sectional top plan view of partially
obstructed
antegrade flow through the valve device of Figure 5A.
[0015] Figure 5C is a schematic, cross-sectional top plan view of
retrograde flow
through the valve device of Figure 5A.
[0016] Figure 5D is a schematic, cross-sectional top plan view of forced
antegrade flow
through the valve device of Figure 5A.
[0017] Figure 6A is a schematic, cross-sectional side view of antegrade
flow through a
body fluid drainage system implanted in a ventricle in accordance with an
embodiment of the
present technology.
[0018] Figure 6B is a schematic, cross-sectional top view of retrograde
flow through
the body fluid drainage system of Figure 6A.
[0019] Figure 7A is a partial schematic view of a body fluid drainage
system in
accordance with a further embodiment of the present technology.
[0020] Figures 7B-7D are schematic views of portions of the body fluid
drainage
system of Figure 7A.
[0021] Figures 8A and 8B are schematic views of external body fluid
drainage systems
installed in different portions of a CSF system in accordance with additional
embodiments of
the present technology.
3
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
DETAILED DESCRIPTION
[0022] The present technology is directed to devices, systems, and methods
for draining
excess body fluids. In one embodiment, for example, a body fluid drainage
system can be
installed between a site of excess body fluid in a patient and a second
location (e.g., an
external receptacle, an internal cavity) that can collect and/or reabsorb the
excess body fluid.
The body fluid drainage system can include a valve device that applies
incremental forces to
an exterior of a catheter to regulate the drainage rate of the body fluid. In
selected
embodiments, the body fluid drainage system can also generate forced flow of
the body fluid
through the catheter to both prevent obstructions and perform diagnostics on
the system.
Certain specific details are set forth in the following description and in
Figures 1A-8B to
provide a thorough understanding of various embodiments of the technology. For
example,
several embodiments of body fluid drainage systems that shunt cerebrospinal
fluid ("CSF")
are described in detail below. The present technology, however, may be used to
drain a
variety of excess body fluids, such as peritoneal fluid, blood, water, and/or
other body fluids.
Additionally, the term "catheter" is used broadly throughout the application
to refer to any
suitable tubing or structure that includes a lumen through which body fluids
can flow. Other
details describing well-known structures and systems often associated with CSF
and other
body fluid drainage systems, shunts, biomedical diagnostics, etc. have not
been set forth in
the following disclosure to avoid unnecessarily obscuring the description of
the various
embodiments of the technology. A person of ordinary skill in the art,
therefore, will
accordingly understand that the technology may have other embodiments with
additional
elements, or the technology may have other embodiments without several of the
features
shown and described below with reference to Figures 1A-8B.
[0023] As used herein, the term "force" refers to the interaction between
an actuator
and a catheter. This term is used broadly, and in some embodiments "pressure"
is an equally
valid term. Additionally, in selected embodiments, the actuator can apply a
force or a
pressure to the catheter by changing the position of the actuator mechanism
(e.g., a linear
shaft, a rotary shaft, a screw shaft) relative to the catheter, thus "actuator
position" may also
be used to describe the interaction between the actuator and the catheter.
[0024] Figure lA is a schematic view of an internal body fluid drainage
system 100
("drainage system 100") implanted in a patient 101 in accordance with an
embodiment of the
present technology. The drainage system 100 can include a catheter 102, a
valve device 104
4
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
over an exterior surface 112 of the catheter 102, and one or more sensors 106
(identified
individually as a first sensor 106a and a second sensor 106b). The drainage
system 100 can
also include a controller 110 that is operatively coupled to the valve device
104 and/or the
sensors 106. As described in further detail below, the valve device 104 can
apply
incremental forces to the exterior surface 112 of the catheter 102 to regulate
body fluid flow
through the catheter 102, and the controller 110 can alter the level of force
applied by the
valve device 104 on the catheter 102 in response to measurements (e.g.,
pressure, flow rate)
taken from the sensors 106.
[0025] As shown in Figure 1A, the catheter 102 can include a proximal
portion 108a
and a distal portion 108b opposite the proximal portion 108a. The proximal and
distal
portions 108a-b of the catheter 102 can be an integrally formed tube or
include two or more
separate tubes joined together using suitable fastening methods (e.g., gluing)
known in the
art. The catheter 102 can be made from a range of polymers, such as silicone,
latex,
thermoplastic elastomers, and/or other suitable tubing materials. In selected
embodiments,
portions of the catheter proximate to the valve device 104 can include
compressible
peristaltic pump tubing (e.g., silicone rubber, polyvinyl chloride), reduced
fouling surfaces,
tubing with different mechanical compliances, and/or other durable elastomeric
materials that
resist fatigue. In other embodiments, the catheter 102 can be made from tubing
with biocides
and/or other anti-biofouling agents that prevent organisms from entering the
drainage system
100 and causing infection. When the catheter 102 includes different materials
and/or sections
of tubing, the different materials and/or portions can be sealed together with
adhesives and/or
other fasteners that provide a liquid-tight seal.
[0026] The proximal portion 108a of the catheter 102 is positioned at a
site of excess
body fluid and the distal portion 108b can be placed in fluid communication
with an internal
receptacle that collects and/or absorbs the body fluid. The proximal portion
108a of the
catheter 102 can include an inlet region 116 with one or more openings (not
visible) in fluid
communication with a site of excess body fluid such that the body fluid can
flow into the
catheter 102. In the embodiment illustrated in Figure 1A, for example, the
inlet region 116 of
the catheter 102 is installed (e.g., via a burr hole) into a ventricle 113 of
the patient's brain to
receive excess CSF. After entering the drainage system 100, the body fluid can
travel in an
antegrade flow through the catheter 102 to the distal portion 108b. The distal
portion 108b
can include an outlet region 118 that expels the excess body fluid into an
internal location.
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
For example, the outlet region 118 can be placed in fluid communication with
the patient's
peritoneal cavity 115, where excess body fluid can reabsorb into the body. In
other
embodiments, the outlet region 118 can expel the body fluid into the atrium of
the heart, the
pleural lining of the lung, the gallbladder, and/or other suitable terminal
locations.
[0027] The valve device 104 can be positioned between the proximal and
distal
portions 108a-b of the catheter 102 to regulate the body fluid flow through
the drainage
system 100. As shown in Figure 1A, for example, the valve device 104 can be
implanted in a
subclavicular pocket of the patient 101. In other embodiments, the valve
device 104 can be
installed in a prefascial or subfascial intra-abdominal region. This intra-
abdominal
positioning is particularly suited for neonates to ease exchange of the valve
device 104 as the
child grows, but also facilitates accessibility to the valve device 104 for
adults.
Advantageously, placement of the valve device 104 in either the subclavicular
pocket or the
intra-abdominal region negates the need to shave the patient's scalp to
perform cranial
surgery in the event that a component requires replacement or repair, and thus
avoids the
need for repeated incisions in the scalp that can cause devascularization,
poor wound healing,
and/or infection. The intra-abdominal valve device 104 also eases the periodic
replacement
of batteries or other power sources. In other embodiments, the valve device
104 can be
installed subcutaneously in other regions of the torso or between another site
of excess body
fluid and a receptacle that can collect and/or reabsorb the body fluid. In
further
embodiments, the valve device 104 can be miniaturized such that it can be
implanted under
the scalp.
[0028] The sensors 106 can measure pressure within the catheter 102, flow
rate of the
body fluid through the catheter 102, and/or other desired measurements
associated with body
fluid drainage through the drainage system 100. Pressure sensors can be small
electrical
sensors positioned along the drainage device 100. Body fluid flow rate through
the catheter
102 can be measured with a non-electrical Rotameter that uses a local or
remote sensor to
read the position of a weighted or buoyant ball that rises and falls within
the catheter 102 in
proportion to the flow rate. In other embodiments, the body fluid flow rate
can be measured
using what is known in the art as the "ice cube test." An improved version of
such a flow rate
sensor includes a resistive electrical heater and temperature sensor embedded
in the body
fluid flow, rather than an external heater/cooler and an external temperature
measurement
device used in conventional ice cube tests. In further embodiments, body fluid
flow rate can
6
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
be measured using what is known as a "tick-tock chamber" that senses the rate
that
specialized chambers refill with the body fluid within the catheter 102.
[0029] As shown in Figure 1A, the sensors 106 can be positioned proximate
to the
outlet and inlet to the valve device 104. Accordingly, the first sensor 106a
can measure the
flow rate and/or the pressure within the proximal catheter 108a before it
enters the valve
device 104 and the second sensor 106b can measure the flow rate and/or
pressure within the
distal portion 108b as it exits the valve device 104. This information can be
used to ensure
the valve device 104 generates the desired drainage rate, to monitor patient
orientation, to
perform diagnostics on the drainage system, and/or derive other desired
measurements or
characteristics. In other embodiments, the drainage system 100 can include
more or less
sensors 106. For example, a pressure sensor 106 can be positioned proximate to
the inlet
region 116 to measure ICP directly.
[0030] The sensors 106 can also be used to derive a pressure at a desired
location (e.g.,
the Foramen of Monroe for ICP) spaced apart from the sensors 106. For example,
the sensors
106 that are positioned proximate to the valve device 104 in the torso of the
patient 101 can
be used to derive ICP. As shown in Figure 1A, the sensors 106 can be
positioned on either
side of the valve device 104 to measure pressure upstream and downstream of
the valve
device 104. When the patient 101 is upright (i.e., standing), the first sensor
106a at the
proximal portion 108a can measure a pressure that is substantially equal to
the ICP plus the
pressure head created by the body fluid in the proximal portion 108a above the
first sensor
106a. The second sensor 106b at the distal portion 108b can measure a pressure
substantially
equal to the pressure at the outlet region 118 (e.g., the peritoneal cavity
115; as is known in
the art, the pressure is approximated as zero relative to atmosphere) plus the
negative
pressure created by the body fluid in the distal portion 108b below the second
sensor 106b.
The pressures from the upstream and downstream sensors 106 can be combined to
derive the
true ICP. For example, when the valve device 104 is positioned midway between
the
ventricle 113 and the outlet region 118, the summation of the two pressure
measurements
from the sensors 106 negates the contribution of pressure head and provides
the true ICP.
[0031] In other embodiments, as described in greater detail below with
reference to
Figures 7A-7D, a pressure reference line can be coupled to the drainage system
100 and used
to compensate for changes in patient position. The pressure reference line
measures the
pressure head between a desired reference location and the sensor 106 at the
valve device 104
7
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
directly. As such, the desired pressure measurement (e.g., ICP) is simply the
difference
between the two measured pressures as taken from two independent sensors
(i.e., the pressure
reference line sensor and the drainage line sensor) or a single differential
pressure sensor.
[0032] The drainage system 100 can also include an orientation sensor (not
shown) to
accurately measure a desired pressure (e.g., ICP) regardless of the
orientation of the patient
101. For example, the orientation sensor can include an accelerometer,
inclinometer, and/or
other orientation sensing device. The orientation sensor is used to determine
the angle of
repose (i.e., standing, lying, or therebetween); such that the measured angle
and the known
length of the proximal portion 108a of the catheter 102 can be used to
calculate the pressure
head. The pressure head can be subtracted from the measured pressure to
calculate the true
ICP.
[0033] The controller 110, e.g., a microprocessor, can read the
measurements taken
from the sensors 106 (e.g., pressure, flow rate, orientation, etc.), store
such measurements and
other information in a database, adjust the position of the valve device 104,
and/or carry out
algorithms to regulate fluid flow through the drainage device 100. For
example, the
controller 110 can compare pressure measurements from the sensors 106 with a
desired ICP
to determine whether to incrementally open or close the valve device 104 and
by what
percentage. For example, when the pressure is lower than a desired pressure,
the controller
110 can incrementally close the valve device 104 to increase the resistance to
antegrade flow
through the catheter 102. If the sensed pressure is higher than desired, the
controller 110 can
incrementally open the valve device 104 to decrease the resistance to
antegrade flow.
Similarly, the controller can also compare the sensed flow rate with a desired
flow rate, and
adjust the position of the valve device 104 accordingly. The controller 110
can also carry out
an algorithm that moves the valve device 104 a predetermined amount each time
a
measurement outside of a desired limit (e.g., desired CSF range) is detected.
Such a control
algorithm can also relate the incremental movement of the valve device 104 to
the magnitude
of the difference between a desired and a measured value. In other
embodiments, a
proportional-integral-derivative ("PID") control algorithm or variations
thereof (e.g., P-only,
PI-only) can control the movement of the valve device 104. As such, the
controller 110 can
manage body fluid flow in real-time to maintain the ICP and/or other desired
parameter
within appropriate limits across a range of changes in pressure or body fluid
generation rate
caused by physiologic processes (e.g., valsalva maneuvers, changes in body
orientation).
8
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
[0034] The controller 110 can include algorithms that save power. For
example, a
tolerance window on the control parameter (e.g., ICP or CSF flow rate) can be
defined such
that the valve device 104 does not change position within the tolerance
window. As another
example, the time between sensor measurements can be adjusted based on the
error between
the desired set point and the measured value, such that less frequent
measurements are made
during periods of small error. These power-saving control algorithms can also
be adapted to
the dynamics of the specific application. During CSF drainage, for example,
significant
changes in CSF production may occur over several hours such that only
infrequent sensor
measurements and valve device 104 movements are necessary for adequate flow
control. As
such, the controller 110 can be configured to ignore unimportant transient
conditions (e.g.,
ICP oscillations due to the cardiac cycle, ICP increases due to coughing or
movement)
removed by averaging sensor measurements and/or frequency filtering.
[0035] Additionally, the controller 110 can also include logic to clear the
valve device
104 of obstructions by incrementally opening the valve device 104 until the
obstruction
clears. For example, the controller 110 can be configured to maintain a
desired ICP such that
when an obstruction within the valve device 104 causes an increase in the
measured pressure,
the control algorithm (e.g., a proportional-integral-derivative) incrementally
or fully opens
the valve device 104 to decrease the resistance to antegrade flow. This
incremental opening
of the valve device 104 allows the obstruction to flow through the valve
device 104 such that
the drainage system 100 can maintain the desired ICP. As described in further
detail below,
in other embodiments, the controller 110 can include logic that clears and/or
prevents
obstructions by flushing the catheter 102 with body fluid.
[0036] As further shown in Figure 1A, the drainage system 100 can include a
time
keeping device 124 (e.g., clock, timer, etc.) that is operatively coupled to
the controller 110.
The controller 110 can use the time keeping device 124 to sense pressure
and/or flow rate at
preset time intervals (e.g., once a minute). Additionally, as explained in
further detail below,
the controller 110 can use the time keeping device 124 to periodically flush
the catheter 102
and/or periodically run diagnostics.
[0037] Additionally, as shown in Figure 1A, the drainage system 100 can
also include a
power source 122 for the valve device 104 and/or other electrical features
(e.g., the time
keeping device 122, the sensors 106, etc.). The power source 122 can be stored
locally
within the drainage system 100. As such, the power source 122 can thus include
a lithium-
9
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
ion cell, a rechargeable battery, and/or other suitable portable power
sources. In selected
embodiments, the internally installed power source 122 can be recharged
remotely using
inductive coupling, kinetic energy generation by M2E of Boise, ID, and/or
other remote
recharging methods known in the art. In other embodiments, the drainage system
100 can
connect to an external recharging station.
[0038] In selected embodiments, the controller 110 can be operatively
coupled to a
wireless communication link 126, such as a WiFi connection, radio signal,
and/or other
suitable communication links that can send and/or receive information. The
wireless
communication link 126 allows measurements from the sensors 106 and/or other
information
to be monitored and/or analyzed remotely. For example, the wireless
communication link
126 allows measurements recorded from the sensors 106 to be accessed at a
doctor's office, at
home by the patient 101, and/or at other remote locations. Additionally, the
drainage system
100 can use the wireless communication link 126 to receive information at a
WiFi hot spot or
other remotely accessible locations. This allows a remote physician to inquiry
the drainage
system 100 regarding particular measurements (e.g., ICP), instruct the
controller 110 to
adjust the valve device 104 accordingly, and/or program sophisticated
algorithms onto the
controller 110 for the drainage system 100 to carry out. Accordingly, the
drainage system
100 can provide more expedient, sophisticated, and personalized treatment than
conventional
CSF shunts, without requiring frequent in-office visits.
[0039] As further shown in Figure 1A, the valve device 104, the controller
110, and/or
other subcutaneously implanted features of the drainage system 100 can be
enclosed within a
housing 128. Accordingly, the housing 128 can be made from a biocompatible
material that
protects the devices stored within from tissue ingrowth, body fluids, and/or
other internal
bodily features that may interfere with the operability of the drainage system
100. In selected
embodiments, the housing 128 can also form a magnetic shield over the devices
within it
such that the patient 101 can undergo magnetic resonance imaging ("MRI") and
similar
procedures without removing the drainage system 100.
[0040] In operation, the drainage system 100 can have generally low power
consumption. For example, the drainage system 100 requires minimal, if any,
continuous
power. In one embodiment, the time keeping device 124 is the only feature of
the drainage
system 100 that continuously draws from the power source 122. Other devices
can draw
from the power source 122 intermittently as needed. For example, the sensors
106 and/or
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
other sensing devices can sense pressure at preset intervals (e.g., once per
minute) and only
draw from the power source 122 at that time. Similarly, any diagnostics and/or
forced flows
(e.g., backflushing, described below) only occur periodically and thus only
require power
occasionally. In selected embodiments, the valve device 104 only requires
power when it
changes position to adjust the pressure and/or flow rates. Without the need
for any
continuous substantial power, the drainage system 100 consumes much less power
than
would be required using a pump to drive body fluid. As described below, the
drainage
system 100 can also include a hybrid mechanical and electrical device that
reduces the
required frequency of actuator movements, and thus further reduces power
consumption.
Accordingly, the drainage system 100 can be configured such that the power
source 122 runs
the drainage system 100 for extended periods of time (e.g., five or more
years), and therefore
does not necessitate frequent surgeries to replace the power source 122.
[0041] Optionally, the drainage system 100 can also include a pump (e.g.,
an electro-
osmotic pump) that can be activated to drive body fluid flow through the
drainage system
100. For example, the controller 110 can include logic that activates the pump
when the
orientation of the patient 101 is such that the body fluid flows in the
reverse direction (i.e.,
retrograde flow) through the catheter 102. In other embodiments, the drainage
system 100
can include other suitable devices and features that facilitate the controlled
drainage of body
fluids.
[0042] The subcutaneously installed drainage system 100 shown in Figure lA
can also
include features that limit the risk of infection during and after
implantation. For example,
components of the drainage system 100 (e.g., the catheter 102, the housing
128) can include
anti-fouling coatings and/or antibiotic impregnated materials. In selected
embodiments,
short-term thermal cooling and heating can be applied to the drainage system
100 as a whole
or components thereof to reduce bacterial colonization during the
perioperative period. In
other embodiments, the housing 128, the valve device 104, and/or other
portions of the
drainage system 100 can be magnetized or otherwise treated to reduce bacterial
growth and
contamination.
[0043] Figure 1B is a schematic view of an external body fluid drainage
system 150
("drainage system 150") implanted in the patient 101 in accordance with an
embodiment of
the present technology. The drainage system 150 includes features generally
similar to the
drainage system 100 described above with reference to Figure 1A. For example,
the drainage
11
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
system 150 can include the catheter 102 having the proximal portion 108a and
the distal
portion 108b, the valve device 104 positioned therebetween, the sensors 106,
and the
controller 110 operatively coupled to the sensors 106 and the valve device
104. Additionally,
like the internal drainage system 100 described above, the external drainage
system 150 can
regulate CSF or other excess body fluid flow using sophisticated and
individualized methods,
and do so while operating as a low power system. However, the drainage system
150 shown
in Figure 1B is installed externally, between the ventricle 113 and an
external receptacle 114.
The external receptacle 114 can be placed in fluid communication with the
outlet region 118
of the catheter 102 such that it can collect the excess body fluid. As such,
the external
receptacle 114 can be a bag or container made from a range of polymers (e.g.,
silicone,
polyvinyl chloride) and/or other suitable materials for storing body fluids.
[0044] In the illustrated embodiment, the external receptacle 114 is
secured to the
midsection of the patient 101 with a belt 120 such that the patient 101 can
remain mobile as
the drainage system 150 removes the excess body fluid. As shown in Figure 1B,
the belt 120
can also carry the housing 128 that contains the valve device 104, the
controller 110, and/or
other devices that operate the drainage system 150. The externally positioned
housing 128
can be made from a durable material (e.g., plastic) that can withstand the
rigors of the outside
environment and substantially protect the components within. Snaps, thread,
hooks, and/or
other suitable fasteners can be used to secure the external receptacle 114
and/or the housing
128 to the belt 120. In other embodiments, the external receptacle 114 and/or
the housing
128 can be secured to other portions of the patient 101 that do not
substantially inhibit the
patient's mobility.
[0045] In further embodiments, such as when the drainage system 100 is used
for
temporary shunting of acute accumulation of the body fluid, the external
receptacle 114 can
be hung on a pole commonly used for IV bags or otherwise affixed to an
external structure.
Additionally, for temporary drainage, the devices within the housing 128 can
also be
positioned apart from the patient 101, such as on a console connected with a
power source.
[0046] Figure 2A is a schematic cross-sectional view of the valve device
104 for use
with the body fluid drainage systems 100 and 150 shown in Figures lA and 1B
and
configured in accordance with an embodiment of the present technology. As
shown in Figure
2A, the valve device 104 can include an actuator 230 positioned over a portion
of the catheter
102. The actuator 230 can apply varying forces to the external surface 112 of
the catheter
12
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
102 to regulate the body fluid flow rate therein. The surface with which the
actuator 230
contacts the catheter 102 can vary in size and shape. For example, the contact
surface can be
flat, rounded, and/or have a different profile or shape. The contact surface
can also vary in
length along the axis of the catheter 102 to spread the force of the actuator
230 across the
catheter 102. For example, controlling drainage of CSF can be accomplished
using contact
lengths of a few millimeters to a few centimeters.
[0047] In the illustrated embodiment, the actuator 230 contacts one side of
the catheter
102 to compress or "pinch" the catheter 102. In other embodiments, the
actuator 230 can
apply force from opposing sides of the catheter 102 or apply force from
multiple angles
around the circumference of the catheter 102 to effectuate a similar
compression or pinching
action. This external compression eliminates the mechanical valve parts within
the catheter
102, and thus prevents the actuator 230 from coming into contact with the body
fluid within
the catheter 102. Accordingly, the body fluid has a clear flow path through
the catheter 102
that substantially reduces or eliminates stagnant flow regions (e.g., internal
mechanical parts)
and obstructions (e.g., build-up on the internal mechanical parts) often
caused by the complex
flow pathways common to conventional shunts. Additionally, in selected
embodiments, the
actuator 230 can be configured to fail in the open position (i.e., not
restricting flow) such that
it does not to impede drainage of the body fluid.
[0048] The actuator 230 can incrementally or continuously change the flow
resistance
of the catheter 102 to regulate drainage rate of the body fluid. For example,
rather than a
binary open-closed valve, the actuator 230 can compress the catheter 102
varying degrees
between the open and closed positions. The actuator 230 can thus adjust the
level of
compression to accommodate a multitude of variables, and precisely regulate
flow rate
through the catheter 102. For example, CSF drainage devices (e.g., the
drainage devices 100
and 150 shown in Figures lA and 1B) can vary the compression of the actuator
230 in
response to the patient's orientation, a siphoning condition, ICP, retrograde
flow, peritoneal
pressure, and/or other variables that affect the desired flow rate. Thus, the
valve device 104
provides sophisticated control of the body fluid drainage.
[0049] Advantageously, despite this precise control, the valve device 104
can also have
generally low power requirements because the valve device 104 only requires
power as it
adjusts the position of actuators 230. Once at a desired position, the
actuator 230 can
maintain its position without power (e.g., "self-braking"). Piezo-electric
actuators (e.g., the
13
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
Squiggle Motor by Newscale Technologies of Victor, New York) include such
incremental
movement and self-braking features. Advantageously, piezo-electric actuators
230 can also
be small, consume little power when they do move, but can also provide
significant force on
the catheter 102. Piezo-electric actuators can also be compatible with MRIs.
In selected
embodiments, the valve device 104 can also be configured to permit fluctuation
within a
desired range (e.g., cardiac effects) and/or transient spikes or troughs
(e.g., coughing) in
pressure and/or flow rate. This prevents the actuator 230 from unnecessarily
changing
positions and unnecessarily consuming power. In other embodiments, the self-
braking
actuator 230 can be combined with a variable resistance component (e.g., a
compliant
interface member described in Figures 3F-3H) such that the valve device 104
can operate
indefinitely without power as long as the pressure and/or flow rate remain
within the desired
limits. These reduced power features of the valve device 104 can be of
particular advantage
for internally implanted valve devices 104 (e.g., the drainage system 100
shown in Figure
1A) because it increases the lifetime of the power source 122 between
recharging cycles or
surgeries to replace the power source 122.
[0050] The actuator 230 can also be configured to close to prevent any
undesired
retrograde flow through the catheter 102. For example, the sensors 236 can
detect a pressure
gradient directed toward the proximal portion 108a of the catheter 102 (e.g.,
toward the
brain) that may be caused by patient orientation (e.g., upside-down),
straining of the
abdomen, low ICPs, and/or other conditions that may induce retrograde flow. In
response to
this negative pressure gradient, the controller 110 (Figures lA and 1B) can
close the actuator
230 to obstruct all flow through the valve device 104. In other embodiments,
flow sensors
and/or pressure sensors positioned elsewhere along the drainage systems 100
and 150 can
sense retrograde flow and trigger the closing of the actuator 230.
Alternatively, the valve
device 104 can include a one-way check valve as a purely mechanical method to
prevent
retrograde flow such that monitoring for retrograde flow with the controller
110 is not
required.
[0051] The force applied by each of the actuator 230 to the exterior
surface 112 and/or
the effect thereof can be monitored by sensors 236 (identified individually as
a first pressure
sensor 236a and a second pressure sensor 236b). As shown in Figure 2A, the
sensors 236 can
be positioned proximate to an inlet portion 238 and an outlet portion 240 of
the valve device
104 to measure the pressure and/or flow rate within the catheter 102 before
and after the body
14
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
fluid exits the valve device 104. The controller 110 can analyze these
pressure or flow rate
measurements to determine whether the valve device 104 produced a desired
pressure or flow
rate, and adjust the positions of the actuator 230 accordingly. In other
embodiments,
additional sensors 236 can be coupled to other portions of the catheter 102 to
measure
additional pressures, flow rates, and/or other desired properties of the flow
through the valve
device 104/
[0052] The
actuator 230 and the sensors 236 can also be used to diagnose flow
problems in the catheter 102. For example, the actuator 230 can be closed, and
the pressure
response can be measured over time and compared to an expected pressure for
unobstructed
flow, to the expected time required for the pressure to return to a baseline
value, and/or to
other pressure related values that can interpret fluid flow. Closing the
actuator 230 during
unobstructed flow results in a generally rapid increase in the pressure
measurement upstream
of the valve device 104, and opening the actuator 230 results in a rapid
decrease in the
pressure measurement as fluid freely flows through the distal portion 108b of
the catheter
102. Little or no pressure increases observed upon closing the actuator 230
indicates an
obstruction in the proximal portion 108a, while a slow decrease in pressure
upon opening the
actuator 230 indicates an obstruction in the distal portion 108b. These flow
diagnostics can
be performed routinely to sense obstructions at their onset. Additionally, the
valve device
104 can be configured to perform these diagnostic tests more frequently when
the potential
for obstructions is higher (e.g., after surgery).
[0053] In other
embodiments, diagnostics can be performed during normal operation
(i.e., no specialized movement and no forced flow) of the drainage systems 100
and 150. For
example, when the valve device 104 uses pressure-based control to maintain a
constant
pressure (e.g., ICP), an actuator 230 consistently operating at a fully-open
position can
indicate a blocked valve device 104 or an obstructed distal portion of the
catheter 102.
Conversely, an actuator 230 consistently operating in a fully-closed position
can indicate an
obstructed proximal portion 108a of the catheter 102.
[0054] In other
normal operation flow diagnostics, pressure levels within a patient can
be tracked (e.g., remotely via the wireless communications link 126 shown in
Figures lA and
1B) and characterized as "acceptable" or "unacceptable" pressure levels. In
the case of a CSF
drainage system, for example, an unacceptable level may be one that induces a
headache.
Using this information, the controller 110 can adjust the valve device 104 to
maintain
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
acceptable ranges of pressure for the particular patient. Thus, the diagnostic
control of the
valve device 104 can provide precise and individualized treatment to ensure
not only that the
excess body fluid is adequately drained, but also adjust to the
particularities of each patient's
needs.
[0055] In other embodiments, flow rate measurements, rather than or in
conjunction
with pressure measurements, can also be used to perform diagnostic tests and
diagnose
blockages. Similar to the pressure sensor driven diagnostics, Rotameters, the
"ice cube test,"
the tick-tock chamber, and/or other flow rate sensors can measure flow rate
during forced or
unforced flow and compare it with a desired flow rate to identify partial or
complete
blockages.
[0056] In other embodiments, the valve device 104 can include more than one
actuator
230. For example, the valve device 104 can include multiple actuators 230 to
provide
redundancy in the event an actuator 230 fails. Additionally, the inlet and
outlet portions 238
and 240 can include multiple actuators 230 in order to vary the location of
constrictions.
This allows the actuators 230 to constrict alternate portions of the catheter
102 when others
have debris build up. In further embodiments, selected actuators 230 can be
designated
solely to close the catheter 102 to obstruct antegrade flow. Other actuators
230 can adjust
continuously between the open and closed positions to regulate flow rate as
described above.
[0057] Figure 2B is a schematic cross-sectional view of a valve device 204
in
accordance with another embodiment of the disclosure. The valve device 204
includes
features generally similar to the valve device 104 shown in Figure 2A. For
example, the
valve device 204 includes the sensors 236 and the incrementally adjustable
actuator 230 at
the exterior surface 112 of the catheter 102. However, the valve device 204
shown in Figure
2B includes additional actuators 230 (identified individually as a first
actuator 230a, a second
actuator 230b, and a third actuator 230c) positioned over different portions
of the catheter
102. One or more of the actuators 230 can provide the incremental force at the
exterior
surface 112 of the catheter 102 in order to regulate flow and/or include power-
saving self-
braking features. Accordingly, like the valve device 104 shown in Figure 2A,
the valve
device 204 can provide sophisticated flow control, but also benefit from the
low power
consumption described above. Additionally, the position of each actuator 230
can be
adjusted independently by the controller 110 to produce the desired flow rate
of the body
fluid through the catheter 102.
16
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
[0058] In the embodiment illustrated in Figure 2B, the valve device 204
further
includes a reservoir 232 positioned between the proximal and distal portions
108a-b of the
catheter 102. The reservoir 232 and the proximal and distal portions 108a-b
can include
generally similar materials and can be formed integrally or sealed together
with adhesives
and/or other fasteners that provide a liquid-tight seal. As shown in Figure
2B, the reservoir
232 can have an exterior surface 234 and a larger cross-sectional dimension
than a cross-
sectional dimension of the catheter 102 such that the reservoir 232 retains a
larger volume of
the body fluid per cross-section than the catheter 102. In the illustrated
embodiment, the
proximal portion 108a, the reservoir 232, and the distal portion 108b can form
a single lumen
through which the body fluid can flow. This singular lumen provides a simple
flow path for
the body fluid that can reduce or eliminate obstruction-prone areas (e.g.,
corners,
intersections between lumens) that exist in more intricate flow paths.
[0059] The reservoir 232 allows the valve device 204 to create forced flow
or
"flushing" through the proximal and distal portions 108a-b of the catheter 102
to clear
obstructions within the catheter 102 and/or enable diagnostics of flow
obstructions. For
example, the valve device 204 can compress the reservoir 232, and the
controller 110 or
remote device can interpret pressure and/or flow rate changes of the forced
flow to identify
partial or complete blockages. The valve device 204 can also periodically
evacuate the
reservoir 232 toward the proximal and/or distal portions 108a-b of the
catheter 102 to break
up any build up within the catheter 102, and thereby reduce the likelihood of
obstructions.
The flow diagnostics and flushing can be performed routinely sense and remove
obstructions
at their onset. The valve device 204 can also perform diagnostic tests more
frequently when
the potential for obstructions is higher (e.g., after surgery).
[0060] In the illustrated embodiment, the third actuator 230c contacts a
large portion of
the exterior surface 234 of the reservoir 232 such that it more rapidly
accelerates the volume
of body fluid out of the reservoir 232. For example, as shown in Figure 2B,
the reservoir 232
has a first length Li and the third actuator contacts the exterior surface 234
of the reservoir
232 along a second length L2 that is substantially equal to the first length
L1. This increased
contact area provides a greater forced flow that can be used to remove
obstructions (e.g.,
protein build up), run diagnostics, or otherwise flush the catheter 102 with
the body fluid. In
selected embodiments, the third actuator 232c can linearly apply force to the
reservoir 232
along the second length L2 to push the body fluid in a desired direction
(e.g., toward the
17
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
proximal portion 108a or the distal portion 108b). In other embodiments, the
backflushing
and/or forward flushing can be performed manually by the patient or caregiver
by pressing on
the reservoir 232 and directing the body fluid in the desired direction. The
backflushing,
forward flushing, and diagnostic operations can be performed either in an
implantable
drainage system 100 or an external drainage system 150.
[0061] The
valve device 204 shown in Figure 2B can also be used in conjunction with
a conventional valve to add flushing and diagnostic operations (e.g., with
flow regulation
provided fully or partially by the conventional valve). For example, to
retrofit the
conventional drainage system, the valve device 204 can be placed in fluid
communication
with a conventional valve device (e.g., a mechanical ball in seat valve
device). The valve
device 204 can then adjust the actuators 230 to generate forced flow and/or
incrementally
regulate fluid flow. If only forced flow is desired, the valve device 204 need
only include the
reservoir 232 and one or more binary actuators that can accumulate body fluid
in the
reservoir 232 and expel it periodically as desired. As such, forced flow
diagnostics can be
performed periodically on the conventional drainage system to detect
obstructions in the flow
path of the body fluid. For example, the reservoir 232 can flush a portion of
the conventional
system, and the pressure response can be compared with the pressure and/or
pressure decay
of an unobstructed flow path. When used with a separate valve, the pressure
response can be
used to test the pressure-flow characteristics of the conventional valve to
monitor its
degradation over time. Alternatively, the flow rate can be monitored to detect
obstructions
and/or monitor the degradation of the conventional valve device.
[0062] Figures
3A-3J are side views of actuators for a body fluid drainage system (e.g.,
the drainage systems 100 and 150 shown in Figures lA and 1B) in accordance
with
embodiments of the present technology. Each of the actuators shown in Figures
3A-3J are
pinch actuators that are incrementally and/or continuously adjustable between
the open and
closed positions. Therefore, as described above, the actuators can compress
the catheter 102
and/or the reservoir 232 (Figure 2B) to incrementally regulate body fluid
flow. Figure 3A,
for example, shows a linear actuator 360 that can move in the directions
indicated by the
arrows to incrementally compress the catheter 102, and thereby change the
resistance within
the catheter 102. Any of the embodiments described below can be combined, can
include
interface members that transfer force from the actuator to the catheter 102,
and/or can include
18
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
other types of actuators, interface members, and/or compliant interface
members that
incrementally compress the catheter 102.
[0063] Figures 3B-3E illustrate embodiments of rotary actuation. For
example, Figure
3B illustrates a cam actuator 362 that compresses the catheter 102 by
adjusting the amount of
its rotation along the catheter 102. Figure 3C shows a lever actuator 366 that
transmits force
to an interface member, such as a contact pad or a contact roller 364. As
indicated by the
arrows, the lever actuator 366 can rotate about a fulcrum to vary the degree
at which the
contact roller 364 compresses the catheter 102. In the embodiment shown in
Figure 3D, the
linear actuator 360 of Figure 3A rotates a lever 367 (i.e., the interface
member contacting the
catheter 102) about the catheter 102 to incrementally increase the resistance
within the
catheter 102. As shown in Figure 3E, another rotary actuator, a screw actuator
369, can
rotate in one direction to apply more force to the catheter 102 and rotate in
the opposite
direction to release force on the catheter 102.
[0064] Figures 3F-3H show actuators that include a compliant interface
member
between the linear actuator 360 shown in Figure 3A and the catheter 102. In
other
embodiments, the actuators shown in Figures 3F-3H can use rotary or other
types of
actuation. Referring to Figure 3F, the compliant member can include a spring
368 or other
compliant material that transmits force from the actuator 360 to the catheter
102 to control
flow. As shown in Figures 3G and 3H, the compliant member can also include a
spring lever
or other flexible lever 370 that rotates about a fulcrum 371 at the catheter
102. In the
embodiment illustrated in Figure 3G, the actuator 360 presses down on the
flexible lever 370
to rotate it varying degrees and transmit the force from the actuator 360 to
the catheter 102.
In the embodiment illustrated in Figure 3H, the actuator 360 can apply force
upward against
the flexible lever 370 such that it rotates and transfers force from the
actuator 360 to the
catheter 102. In operation, the spring 368, the flexible lever 370, and/or
other compliant
interface members provides a degree of passive actuation that adjust the force
applied to the
catheter 102 without moving the actuator 360. Accordingly, body fluid drainage
systems
(e.g., the drainage systems 100 and 150 shown in Figures 1A and 1B) including
passive
actuators can consume less power.
[0065] Figures 31 and 3J show purely mechanical actuators that require no
power to
operate. For example, Figure 31 shows an actuator 330 that can regulate the
flow rate
through the catheter 102. The actuator 330 can include actuator contacts 335
(identified
19
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
individually as a first actuator contact 335a and a second actuator contact
335b) connected to
one another by a lever arm 331 having a first lever arm portion 331a and a
second lever arm
portion 33 lb. The desired flow rate characteristics of the actuator 330 can
be obtained by
changing the relative lengths of the first and second lever arm portions 331a-
b and the
relative areas of the first and second actuator contacts 335a-b. As shown in
Figure 31, when
the upstream pressure increases, the force on the first actuator contact 335a
increases. The
lever arm 331 transmits this force to the second actuator contact 335b such
that it compresses
the catheter 102. The force on the catheter 102 increases the valve
resistance, and thereby
maintains an approximately constant flow rate through the valve device without
requiring any
power.
[0066] Figure 3J shows an actuator 333 that can regulate the upstream
pressure in the
catheter 102. Similar to the actuator 330 shown in Figure 31, the actuator 333
includes the
actuator contacts 335 and the lever arm 331. However, the lever arm 331 shown
in Figure 3J
is bent or otherwise twisted such that the actuator contacts 335 act on
opposing sides of the
catheter 102. The desired upstream pressure can be obtained by manipulating
the relative
lengths and areas of the lever arms 331 and the actuator contacts 335. As
shown in Figure 3J,
when the upstream pressure increases, the force on the first actuator contact
335a increases.
The lever arm 331 transmits the force to the second actuator contact 335b such
that it
removes force from the catheter 102. This increases the opening of the
catheter 102, and thus
decreases the valve resistance to relieve the pressure buildup. In selected
embodiments, the
actuators 330 and 333 shown in Figures 31 and 3J can also be configured to
prevent
retrograde flow. In further embodiments, multiple interacting lever arms 331
and actuator
contacts 335 can be combined to enhance flow and/or pressure control.
Additionally, the
mechanical actuators can be assisted by electrically-powered actuators to
provide a more
sophisticated control with lower power draw.
[0067] In other embodiments, other devices or methods that compress or
otherwise
constrict the catheter 102 and/or the reservoir 232 can be used to control
flow rate. For
example, the catheter 102 can be twisted incrementally about its longitudinal
axis to create a
variable resistance. As another example, the catheter 102 can be wound (e.g.,
either a partial
turn or many turns) around a shaft or other solid object, and the catheter 102
can then be
stretched to create tension that causes variable flow through the catheter
102. The catheter
102 can also be turned back on itself varying degrees to form one or more
pinch points that
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
can incrementally adjust flow rate. This actuation method can be advantageous
because it
can provide a level of passive activation, requires low force to vary the flow
therein, and thus
has a low power requirement.
[0068] Figures 4A and 4B are side and perspective views, respectively, of
reservoirs
432 for a body fluid drainage system (e.g., the drainage systems 100 and 150
shown in
Figures lA and 1B) in accordance with embodiments of the present technology.
As shown in
Figure 4A, the reservoir 432 can include a tubular body 472 that has a larger
cross-sectional
area than the catheter 102 to which it connects. The tubular body 472 can be
formed
integrally with the catheter, and can therefore include the same material as
the catheter 102.
In other embodiments, the tubular body 472 can include materials that are
different from
those of the catheter 102. For example, the tubular body 472 can include a
compliant
material that is too elastic for the entire length of the catheter 102, but
can advantageously
expand to hold a desired volume of the body fluid within the reservoir 232.
[0069] As shown in Figure 4B, the reservoir 432 includes a chamber 474. The
chamber
474 shown in Figure 4B has a generally flat, rectangular shape, but can have
other suitable
shape (e.g., spherical, cylindrical) for the reservoir 424. In selected
embodiments, the
chamber 474 can include a less compliant material than the catheter 102, but
can also include
one or more compliant regions that can be compressed by the actuator 360. In
other
embodiments, the reservoir 432 can have other suitable configurations that can
contain a
greater cross-sectional volume than the catheter 102.
[0070] Figures 5A-5D are schematic, cross-sectional top plan views of body
fluid flow
through the valve device 204 of Figure 2B in accordance with an embodiment of
the present
technology. Figure 5A, for example, shows the valve device 204 with all
actuators 230 in an
open position to provide unobstructed antegrade flow through a valve device
204. As shown
in Figure 5B, select actuators 230 can apply force against the exterior
surface 112 of the
catheter 102 to slow the flow rate of the body flow. More specifically, Figure
5B shows the
first actuator 230a in an intermediate position (i.e., between fully open and
fully closed) that
partially obstructs antegrade flow through the proximal portion 108a of the
catheter 102. The
second actuator 230b is also in an intermediate position, but applies a
greater force to the
exterior surface 112 of the catheter 102. Partially closed actuators 230 can
be of particular
advantage to prevent siphoning of the body fluid. Any adjustment (e.g.,
partially closed,
closed, or open) of the actuators 230 can occur successively or in tandem.
21
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
[0071] The valve device 204 can also adjust to force antegrade flow and
retrograde
flow to "flush" the catheter 102 with the body fluid. As shown in Figure 5C,
for example, the
second actuator 230b can be closed to stop fluid flow through the distal
portion 108b of the
catheter 102, and the third actuator 230c can compress the reservoir 232 to
evacuate the body
fluid collected therein. This forces the body fluid through the open first
actuator 230a into
the proximal portion 108a of the catheter 102, and thereby clears obstructions
and loosens
build up of blood, cellular debris, postoperative debris, and/or other debris
within in the
proximal portion 108a and/or the inlet region of the catheter 102.
[0072] Similar to the backflushing shown in Figure 5C, the valve device 204
can also
adjust to provide a forward flush. For example, as shown in Figure 5D, the
first actuator
230a can close to stop fluid flow above it, and the third actuator 230c can
compress the
reservoir 232 to force the body fluid through the distal portion 108b of the
catheter 102. This
forced flow provided to either the proximal or distal portions 108a-b of the
catheter 102 can
dislodge obstructions (e.g., blood, cellular debris, postoperative debris) in
the catheter 102
and disrupt tissue invasion that may occur at the inlet or outlet regions (not
shown) of the
catheter 102.
[0073] In selected embodiments, the valve device 104 can perform periodic
backflushing and forward flushing to reduce the likelihood of obstructions.
The periodic
forced flow can also be used in conjunction with the diagnostic tests
described above. In
other embodiments, the backflushing and/or forward flushing can be performed
manually by
the patient or caregiver by pressing on the reservoir 232 and directing the
body fluid in the
desired direction.
[0074] Figures 6A and 6B are illustrations of antegrade flow and retrograde
flow,
respectively, through the inlet region 116 of the body fluid drainage systems
100 and 150 of
Figures lA and 1B described above in accordance with an embodiment of the
present
technology. In the illustrated embodiment, the inlet region 116 is inserted
into the lateral
ventricle 113 such that the drainage systems 100 and 150 can remove excess CSF
fluid. As
shown in Figure 6A, the inlet region 116 of the catheter 102 can include a
plurality of
openings 676 through which excess CSF can enter the drainage systems 100 and
150. As
shown in Figure 6B, the CSF can be directed in retrograde flow via the valve
device 104. For
example, the valve device 104 can be configured as shown in Figure 5C to force
flow through
the proximal portion 108a of the catheter 102. This can expel CSF out of the
openings 676
22
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
and clear the inlet region 116 of obstructions. For example, as shown in
Figure 6B, the inlet
region 116 can be obstructed with choroid plexus ingrowth, ependymal lining
ingrowth,
and/or other tissue ingrowth 617. The forced retrograde flow of CSF can
mobilize an
ingrown portion 678 such that it no longer blocks the openings 676 of the
inlet region 116.
In other embodiments, the valve device 104 can force antegrade flow through
the distal
portion 108b of the catheter to reduce the likelihood of tissue ingrowth or
other obstructions
at the outlet region 118 (not shown) of the catheter 102.
[0075] Figure 7A is a partial schematic view of a body fluid drainage
system 700
("drainage system 700") in accordance with a further embodiment of the present
technology,
and Figures 7B-7D show enlarged portions of the drainage system 700 of Figure
7A. The
drainage system 700 can include features generally similar to the external
drainage system
150 described above with reference to Figure 1B. For example, the drainage
system 700 can
include a catheter 702 that has a proximal portion 708a at the source of
excess body fluid and
a distal portion 708b that drains the excess body fluid to an external
receptacle 714. In other
embodiments, the drainage system 700 can discharge the excess body fluid to an
internal
receptacle, such as described above with reference to Figure 1A. As shown in
Figure 7C, the
drainage system 700 can also include a valve device 704 that applies forces to
the exterior of
the catheter 102 to regulate the drainage of the body fluid.
[0076] As shown in Figure 7A, the drainage system 700 further includes a
pressure
reference line 780 ("reference line") and a controller interface 782. Both can
be coupled to a
controller 710 (Figure 7C) that has generally similar features as the
controller 110 described
above. The reference line 780 can include a fluid-filled tube that extends
between a flexible
end cap 787 at a first end portion 781a and a pressure sensor 784 at the
second end portion
781b. In a CSF drainage system, the fluid that fills the reference line 780
can be a silicone
oil or other fluid that has a density substantially equal to CSF. In other
embodiments, the
reference line 780 can include a fluid that has a density substantially equal
to the body fluid
being drained. In further embodiments, the reference line 780 can be filled
with a fluid that
has a density different from the body fluid being drained, and the differing
densities can be
accounted for in an associated algorithm.
[0077] As shown in Figure 7B, the end cap 787 can include a flexible
silicone balloon,
bag, and/or other flexible structure 789 and a protective cage or barrier 791.
The barrier 791
can prevent accidental compression of the flexible structure 789 and can be
vented to allow
23
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
pressure communication with the environment external to the barrier 791. For
an implantable
device, the barrier 791 can be designed to prevent body tissue from
interacting with the
flexible structure 789. In one embodiment, the end cap 787 has a diameter of a
few
millimeters and a length of approximately 1 cm to discretely fit over the
patient's ear as
shown in Figure 7A. In other embodiments, the end cap 787 can have larger or
smaller
dimensions to accommodate its placement.
[0078] To obtain a desired pressure, the end cap 787 can be positioned
proximate to the
desired pressure measurement, and the pressure sensor 784 can be placed in
fluid
communication with the catheter 702 (i.e., the drain line). For example, in
the illustrated
embodiment, the end cap 787 is mounted proximate to the Foramen of Monroe to
measure
ICP, and the pressure sensor 784 is placed in fluid communication with the
catheter 702. The
difference between the pressure in the reference line 780 and the pressure of
the catheter
702A can be determined using a differential pressure sensor and/or two
independent pressure
sensors. This differential pressure measurement incorporates a direct
measurement of the
pressure head caused by the body fluid in the catheter 702. Thus, the
differential pressure
measurement is equal to the pressure of the drainage system 700 at the end cap
787 (e.g.,
ICP). Advantageously, this direct measurement of the pressure head allows the
reference line
780 to automatically compensate for positional changes of the pressure sensor
784 and the
valve device 704 to which it is coupled. Therefore, the drainage system 700
can derive an
accurate pressure measurement regardless of movement of the patient 701 and/or
the valve
device 704. Accordingly, the drainage system 700 measures ICP more accurately
than
conventional CSF drainage systems that require the patient 701 to remain
motionless during
drainage procedures.
[0079] As shown in Figure 7C, the proximal portion 708a of the catheter 702
and the
second end portion 781b of the pressure reference line 780 can extend into a
cartridge 783.
The cartridge 783 can also house the pressure sensor 784 of the pressure
reference line 780, a
flow rate sensor 784, and/or other pressure and flow rate sensors (not shown)
that contact
CSF or other body fluids. In other embodiments, the pressure sensors and flow
sensors can
measure pressure and flow rate through the wall of the catheter 702 such that
they do not
contact the body fluid. Additionally, as shown in Figure 7C, the cartridge 783
can also
include an electrical connection 785 that couples the drainage system 700 to a
power source
(not shown).
24
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
[0080] In selected embodiments, the cartridge 783 is disposable such that
it can be
coupled to reusable portions of the drainage system 700 that do not contact
the body fluid.
For example, as shown in Figure 7C, the disposable cartridge 783 can be
coupled with the
controller 710 and the valve device 704. In selected embodiments, the
disposable cartridge
783, the reusable controller 710, and/or other reusable components can be
designed with
registration features and positive engagement mechanisms such that they can
only be
assembled with the proper geometry. As such, the portions of the drainage
system 700 that
are contaminated with body fluid (i.e., the portions stored within the
cartridge 783) can be
thrown out after use, while the controller 710, the valve device 704, and
other more intricate
devices (e.g., flow sensors) can be conserved and used with a plurality of
disposable
cartridges 783.
[0081] Figure 7D shows of the controller interface 782 of the drainage
system 700 of
Figure 7A. The controller interface 782 can include one or more user controls
786 (identified
individually as a first user control 786a and a second user control 786b) and
displays
(identified individually as a first display 788a and a second display 788b),
both operatively
coupled to the controller 710. The user controls 786 can allow a user (e.g., a
medical
professional) to select and adjust the desired condition for pressure or flow
rate, as well as the
tolerances of the drainage system 700. For example, as shown in Figure 7D, the
user controls
786 can change the desired ICP and/or flow rate of the drainage system 700.
The user
controls 786 can be coupled to the controller 710 such that the controller 710
can adjust the
valve device 704 to output the selected ICP or flow rate. The displays 788 can
show the
actual measured ICP and drainage rate to ensure the drainage system 700 meets
the selected
tolerances. Additionally, as shown in Figure 7D, the controller interface 782
can also include
a warning signal 790 (e.g., a light, a bell) that activates when conditions do
not allow proper
drainage. For example, the warning signal 790 can be a light that illuminates
when the
external receptacle 714 is positioned too high relative to the rest of the
drainage system 700.
[0082] Figures 8A and 8B are schematic views of body fluid drainage systems
800 and
850 installed in a CSF system 819 in accordance with additional embodiments of
the present
technology. The body fluid drainage systems 800 and 850 can include generally
similar
features as the drainage system 700 described above with reference to Figures
7A-7D. For
example, the body fluid drainage systems 800 and 850 include a pressure
reference line 880
CA 02793672 2012-09-18
WO 2011/116393 PCT/US2011/029261
mounted over the equivalent external location of the Foramen Monroe to
automatically
account for movement of a patient 801 and/or an external receptacle (not
shown).
[0083] As shown in Figure 8A and 8B, the drainage systems 800 and 850 can
drain
CSF from different portions of the CSF system 819. For example, in the
embodiment
illustrated in Figure 8A, the body fluid drainage system 800 includes a
catheter 802 that has a
proximal portion 808a inserted into the upper portion (e.g., a ventricle) of
the CSF system
819. Similar to the drainage systems 100, 150, and 700 shown in Figures 1A,
1B, and 7A-
7D, the cranially inserted body fluid drainage system 800 can drain fluid
through a distal
portion 808b of the catheter 102 to an external receptacle or internal cavity.
[0084] The body fluid drainage system 850 shown in Figure 8B includes a
catheter 892
inserted into the patient's lumbar region the lower portion of the CSF system
819. Similar to
the cranially inserted drainage system 800 described above, the body fluid
drainage system
850 can drain body fluid (e.g., CSF) from a proximal portion 894a of the
catheter 892 to a
distal portion 894b that is in fluid communication with an external receptacle
or internal
reabsorbtion cavity. Advantageously, despite the different insertion points of
the body fluid
drainage systems 800 and 850, the pressure reference line 880 can still adjust
for movement
of the patient 801 to allow for accurate ICP measurements.
[0085] From the foregoing, it will be appreciated that specific embodiments
of the
present technology have been described herein for purposes of illustration,
but that various
modifications may be made without deviating from the spirit and scope of the
disclosure. For
example, the pressure reference lines 780 and 880 shown in Figures 7A-8B can
be added to
the body fluid drainage systems 100 and 150 shown in Figure lA and 1B.
Additionally, the
pressure reference lines 780 and 880 can be implanted in a patient, rather
than externally
mounted as in Figures 7A-8B. Aspects of the disclosure described in the
context of particular
embodiments may be combined or eliminated in other embodiments. For example,
the valve
device 104 shown in Figure 2A can include additional actuators that control
body fluid flow
through the catheter 102. Further, while advantages associated with certain
embodiments of
the disclosure have been described in the context of those embodiments, other
embodiments
may also exhibit such advantages, and not all embodiments need necessarily
exhibit such
advantages to fall within the scope of the disclosure. Accordingly,
embodiments of the
disclosure are not limited except as by the appended claims.
26
